Background: Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors, and known to have limited treatment options.We investigated the treatment outcome of pazopanib, an oral multi-tyrosine kinase angiogenesis inhibitor, in patients with advanced STS. Methods: A total of forty-four patients with relapsed or refractory STS with metastatic disease received pazopanib for salvage chemotherapy after one or more cytotoxic regimens. All patients were analyzed by histologic subtype, FNCLCC grade and existence of liver involvement and locoregional disease. Results: The majority of patients were male (n=26, 59%) and one (n=9, 20.5%) or two (n=15, 34.1%) previous chemotherapy was introduced. Common histologic subtypes were as follows; leiomyosarcoma (n=9), angiosarcoma (n=6), malignant perpheral nerve sheath tumor (n=5) and liposarcoma (n=2). 9 patients (20.5%) achieved confirmed partial response and 16 patients (.36.5%) revealed stable disease, resulting in disease control rate (DCR) of 56.8% (95% CI, 41.8-71.8). The median progression free survival (PFS) and overall survival (OS) were 100 and 199 days, respectively. The non-liposarcoma group (such as leiomyosarcomas, angiosarcomas and osteosarcomas, n=38) demonstrated significantly prolonged PFS than pediatric type and liposarcoma group (including rhabdomyosarcomas and small round cell sarcomas, n=6) (P<0.001). The median PFS were 132 and 115 days for angiosarcomas (n=6) and leiomyosarcomas (n=9), while rhabdomyosarcomas (n=3) and liposarcomas (n=2) patients demonstrated 27 and 39 days, respectively. Conclusions: Pazopanib demonstrated better antitumor activity for the patients with angiosarcoma and leiomyosarcoma compare to liposarcoma and pediatric type sarcoma.